报告发布方：中金企信国际咨询 项目可行性报告&商业计划书专业权威编制服务机构（符合发改委印发项目可行性研究报告编制要求）-中金企信国际咨询：集13年项目编制服务经验为各 类项目立项、投融资、商业合作、贷款、批地、并购&合作、投资决策、产业规划、境外投资、战略规划、风险评估等提供项目可行性报告&商业计划书编 制、设计、规划、咨询等一站式解决方案。助力项目实施落地、提升项目单位申报项目的通过效率。 （1）骨科器械市场运行现状及发展趋势分析：骨科是各大医院最常见的科室之一，骨科疾病包括影响肌肉骨骼系统的损伤及病症，其中包括骨骼、肌肉、 神经、关节、韧带、肌腱及其他结缔组织，任何该等组织或结构的损伤均可能源于慢性疾病或急性损伤。 目前，随着医疗技术的不断进步，骨科医疗器械行业正经历着快速的技术创新和产品升级。新材料、新工艺和新技术的应用不断推动产品的创新和升级，提 高了产品的质量和性能，使得许多以往不能治疗或难以治疗的损伤疾病获得了新的治疗机会。随着临床医学、材料学等的进步，骨科医疗器械的创新与进步 为改善临床痛点和提升手术质量与效率提供了更多的可能，而微创手术、精准治疗、新材料等变革性的产品创新会有望为骨科疾病治疗 ...

Group 1: Industry Overview - The orthopedic consumables industry has shown signs of recovery after three years of collective procurement, with leading domestic companies reporting a rebound in Q1 2025 and continued growth in subsequent quarters [1] - Many top domestic orthopedic companies have disclosed their Q3 2025 financial reports, showing both revenue and net profit growth, particularly driven by expansion into overseas markets [1][3] - The global orthopedic medical device market is projected to grow to $62.22 billion in 2024 and exceed $94 billion by 2032, with a stable annual growth rate of 5.3% [3] Group 2: Company Performance - Companies like Chuangli Medical, Dabo Medical, and Weigao Orthopedics have seen significant net profit growth rates of 76.69%, 44.85%, and 52.43% respectively in H1 2025, while Aikang Medical's net profit growth was only 15.34% [2] - Aikang Medical reported a 45% increase in revenue compared to the peak before collective procurement, outperforming competitors like Weigao Orthopedics and Sanyou Medical, which saw revenue declines of 64% and 52% respectively [3] - Aikang Medical's stock price has been relatively stagnant, with a year-to-date increase of only 17.23%, despite the overall industry recovery [1][2] Group 3: Market Dynamics - Investors are currently favoring companies that are accelerating their overseas market expansion, as evidenced by the stock performance of companies like Chuangli Medical, which has seen its overseas revenue reach 40% [4] - Aikang Medical's focus remains primarily on the domestic market, with only 18% of its revenue coming from overseas, indicating a significant gap compared to its peers [4] - The stock price of Aikang Medical has experienced high volatility, with a range of 23.10% during a recent three-month period, while maintaining a stable average cost around 6 HKD [7] Group 4: Technical Analysis - Following a significant drop in stock price on August 28, Aikang Medical's stock entered a period of low volatility and consolidation, with no substantial volume increase to support a breakout [6][7] - The Bollinger Bands indicator suggested a "false breakout," indicating that it may not be the optimal time for short-term investors to enter [6] - The stock has been trading within a narrow range, with a support level established above 5.52 HKD, indicating a concentrated accumulation of shares [7] Group 5: Market Position and Future Outlook - Aikang Medical's average market capitalization during the review period is 6.349 billion HKD, slightly above the threshold for inclusion in the Hong Kong Stock Connect [10] - The upcoming review period for the Hong Kong Stock Connect is critical, as Aikang Medical needs to maintain its market capitalization to avoid being removed from the list [10] - Recent buying activity from mainland investors suggests a positive outlook for Aikang Medical's stock price rebound, with its PE ratio now at 19.51, below the industry average [15]

Core Viewpoint - Weigao Co., Ltd. reported a steady performance in its orthopedic segment, with revenue growth and significant profit increase in the third quarter of 2024 [1] Financial Performance - The company achieved a revenue of 1.106 billion yuan in the first three quarters, representing a year-on-year increase of 2.12% [1] - The net profit attributable to shareholders reached 207 million yuan, marking a year-on-year increase of 26.24% [1] - Basic earnings per share were reported at 0.52 yuan [1] Market Dynamics - The overall execution of bulk purchasing in orthopedics remained stable during the reporting period [1] - The market share of leading domestic brands in the orthopedic sector continued to rise [1] Strategic Initiatives - The company is undergoing a transformation in its sales model, focusing on professional departments for business unit division [1] - Efforts to optimize and upgrade the marketing structure have been implemented, enhancing the professionalism and flexibility of the sales team [1] - These initiatives have led to sustained growth in revenue and sales volume across product lines [1]

Group 1 - The global medical device market is expected to reach $862.6 billion by 2030, with a CAGR of 5% from 2025E to 2030E, driven by factors such as aging population, rising chronic disease prevalence, medical technology advancements, policy support, and improved healthcare systems [1] - In 2025, the market share distribution is projected as follows: North America (32%), Europe (25%), China (8%), Asia-Pacific (19%), Latin America (11%), and Middle East & Africa (5%) [1] - The market segments are expected to be distributed as follows: high-value consumables (32%), low-value consumables (12%), medical imaging equipment (12%), in vitro diagnostics (13%), and others (31%) [1] Group 2 - The valuation of leading global medical device companies shows significant differentiation, with high-growth segments enjoying P/E ratios between 31-57x for 2025E, while mature platform companies typically have P/E ratios of 13-18x for 2025E [2] - The core reason for valuation differentiation is the market's varying expectations for future growth and the technological barriers/sustainable advantages within specific segments [2] Group 3 - Eight key segments identified for potential growth include electrophysiology, renal denervation (RDN), complex vascular interventions, structural heart, neuroscience, surgical robotics, endoscopy, and glucose management [3] - These segments are expected to experience upgrades in procedures or product iterations, or may open up untapped markets through new technologies, leading to significant commercialization opportunities [3] - High-growth leaders in these segments may enjoy long-term premium valuations due to their high barriers to entry, while traditional giants may boost performance and valuation through significant product launches [3]

Group 1 - The core point of the news is that southbound funds have significantly increased their holdings in MicroPort Scientific Corporation (00853.HK), with a total net increase of 13.18 million shares over the last five trading days and 47.15 million shares over the last twenty trading days [1][2] - As of October 17, 2025, southbound funds hold 876 million shares of MicroPort, accounting for 45.8% of the company's total issued ordinary shares [1][2] - The daily changes in shareholding show fluctuations, with a notable increase of 4.95 million shares on October 16, 2025, and a decrease of 519,300 shares on October 15, 2025 [2] Group 2 - MicroPort Scientific Corporation specializes in the manufacturing and sales of medical devices, with divisions focused on orthopedic, cardiovascular, neuro-interventional, surgical, robotic, cardiac rhythm management, and heart valve products [2]

Core Viewpoint - The company reported a slight decline in revenue but a significant increase in net profit, indicating effective cost management and market strategy amidst a growing orthopedic medical device market driven by demographic and policy changes [2][3]. Financial Performance - The company achieved operating revenue of 741 million yuan, a year-on-year decrease of 1.28% [2]. - The net profit attributable to shareholders was 142 million yuan, reflecting a year-on-year increase of 52.43% [2]. - A mid-term dividend proposal was announced, with a cash dividend of 1 yuan per 10 shares (tax included) [2]. Market Strategy - The company maintained stable execution of orthopedic bulk procurement, ensuring continuous market share growth in procurement products while also expanding into incremental markets [2]. - Efforts included structural adjustments, channel integration, and refined management of marketing expenses to reduce sales costs and enhance performance [2]. Industry Trends - The orthopedic medical device market is experiencing steady growth due to an aging population, increased health awareness, and rising demand for orthopedic surgeries [2]. - National policies are accelerating the domestic substitution process, particularly in trauma and spine sectors, providing opportunities for leading domestic companies to expand market share and enhance industry concentration [2]. Innovation and R&D - The company focused on expanding its product lines in response to clinical surgical method changes, particularly in minimally invasive spine surgery, sports medicine, and orthopedic repair and regeneration [3]. - During the reporting period, the company obtained 16 Class I product registration certificates, 15 Class II medical device registration certificates, and 12 Class III medical device registration certificates [3]. International Expansion - The company is advancing its international strategy by establishing sales channels and effectively promoting R&D projects in overseas markets [3]. - A "three-tier market" development strategy is being implemented, focusing on strategic markets (Indonesia, Brazil, Russia, Thailand), consolidating existing trade markets (Central Asia, Africa), and entering new markets (Mexico, Saudi Arabia, Europe) [3]. - The company achieved overseas revenue of 43.21 million yuan, representing a year-on-year growth of 19% [3].

General Information - Shandong Weigao Orthopedic Device Company Limited is established as a joint-stock company according to the Company Law and Securities Law of the People's Republic of China [2][3] - The company was registered in Weihai City and has a registered capital of RMB 400 million [2][3] - The company went public on June 30, 2021, with an initial public offering of 41,414,200 shares [2][3] Company Structure - The company is a permanent joint-stock company with the chairman serving as the legal representative [3] - The legal representative's civil activities conducted on behalf of the company will have legal consequences for the company [3] - Shareholders are liable for the company's debts only to the extent of their subscribed shares, while the company is liable for its debts with all its assets [3] Business Objectives and Scope - The company's business objective is to provide high-quality orthopedic medical devices and contribute to the development of the orthopedic medical device industry [4] - The business scope includes the sale and production of various classes of medical devices, as well as import and export activities [4] Share Issuance and Management - The company issues shares in the form of stocks, adhering to principles of openness, fairness, and justice [5] - The total number of shares issued by the company is 400 million, with 358,585,800 shares issued prior to the public offering [5] - All issued shares are ordinary shares, and the company does not provide financial assistance for acquiring its shares, except under specific conditions [6][7] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, and participation in company meetings, as well as the right to request information and documents [10][11] - Shareholders must comply with laws and the company's articles of association, and they are liable for damages caused by abusing their rights [15][16] Governance and Decision-Making - The company’s highest authority is the shareholders' meeting, which has the power to elect directors, approve financial reports, and make significant corporate decisions [46][47] - Decisions requiring a special resolution must be approved by at least two-thirds of the voting rights present at the meeting [81][82] Legal Compliance and Accountability - The company must comply with legal requirements for convening meetings and making decisions, and shareholders can seek legal recourse if the company fails to adhere to these regulations [36][39] - The company is obligated to disclose information regarding significant events and decisions to ensure transparency and accountability [12][18]

Core Viewpoint - Dabo Medical's stock price increased to 58.69 yuan as of August 25, 2025, reflecting a rise of 0.28 yuan or 0.48% from the previous trading day, indicating positive market sentiment towards the company [1] Company Overview - Dabo Medical specializes in the research, development, production, and sales of orthopedic medical devices, with products covering trauma, spine, joints, and sports medicine [1] - The company is part of the medical device sector and the Fujian region, and it has been included in the 2025 mid-term report pre-increase concept [1] Market Performance - On August 25, 2025, the trading volume was 319 million yuan, with a turnover rate of 1.89% [1] - Dabo Medical was recently included in FTSE Russell and S&P related indices, leading to an increase in market performance expectations [1] Capital Flow - On August 25, 2025, there was a net outflow of 1.4897 million yuan in main funds, with a cumulative net outflow of 101 million yuan over the past five days [1]

Group 1 - The stock price of Chunli Medical as of July 31, 2025, closed at 22.12 yuan, down by 0.38 yuan, representing a decline of 1.69% from the previous trading day [1] - The trading volume on that day was 30,700 lots, with a transaction value of 0.69 billion yuan, and the stock experienced a fluctuation of 5.56% [1] - Chunli Medical specializes in the research, development, production, and sales of orthopedic medical devices, covering areas such as joints, spine, and trauma [1] Group 2 - The company announced a cash dividend plan for the fiscal year 2024, proposing a distribution of 0.49 yuan per 10 shares, with the record date set for July 31 [1] - On July 31, Chunli Medical experienced a net outflow of main funds amounting to 8.61 million yuan, which accounted for 0.13% of its circulating market value [1]

为给予更多优秀骨科技术公司、医疗机构、骨科器械制造商及其他相关单位充分的时间准备和完善申报材料，主办方 骨未来 、 思宇 MedTech 现决定将 奖项评选报名截止时间延期至 2025年3月17日24:00 。 此次延期旨在为有意参选的各方提供更充裕的时间窗口，以便大家能够更全面、深入地 展示自身在骨科医疗器械领域的创新成果与卓越 贡献，分享前沿经验，推动骨科医疗技术的持续进步 。 请有意参选的单位务必在新的截止日期前，通过以下链接提交完整的申报资料 ： https://docs.qq.com/form/page/DUGJueWNLeXVQVExX 评奖通知： 奖项亮点： 成立8年的专业媒体"思宇MedTech"旗下"骨未来"+学术媒体"智汇骨"组织 ， 兼具权威性+影响力 全球宣传，美通社、美联社、路透社等同步报道； 国内主流传统媒体同步报道（覆盖科技日报、中国青年报、新华网、 健康报、北京日报等）； 获奖结果常驻骨未来文章底栏，每天曝光、长达一年；一对一推送骨未来&思宇MedTech覆盖的投资机构、合作医院、政 府机构等。 中关村展示中心会议中心 一、颁奖日期 如有任何疑问或需进一步协助，可随时联系骨未来 ...